Not bad - beat on revenue; met expectations of a nickel loss per share. The analysts seemed to be very upbeat, offering lots of attaboys regarding accomplishments for the year and the 2013 outlook. What really resonated with me is that the company seems to be taking a very practical approach on R&D - planning to hover around the cash break-even level in order to minimize cash burn while continuing to invest in the business. It doesn't seem like we are facing dilution any time soon, especially with the two latest foreign marketing deals providing upfront cash payments. I wouldn't be surprized to see some research notes with a positive slant in the coming days from the analysts.